Skip to content

Dr. Jeff Shuren, FDA CDRH Director, to Retire

 | 

On July 23, 2024, Dr. Jeff Shuren, the director for the Center for Devices and Radiological Health (CDRH), announced that he will retire.  Dr. Shuren became director of the CDRH in 2009.  As director of the CDRH, Dr. Shuren oversaw the approval of medical devices and monitoring of radiation-emitting products.  He implemented several programs, including the Breakthrough Devices Program and National Evaluation System for health Technology (NEST). During Dr. Shuren’s tenure, the CDRH become more efficient. Approval of medical devices has increased five-fold. Importantly, the CDRH also approves between 50 and 70 percent of novel devices in the United States before, or in parallel, with other countries, giving American patients access to life-changing technologies earlier.  FDA Comissioner Robert Califf described Dr. Shuren as “a catalyst for the modernization of medical device regulation and innovator in every sense of the word.” AdvaMed President and CEO Scott Whitaker also praised Dr. Shuren, noting Dr. Shuren’s ability to “balance the ultimate goal of medical device safety and effectiveness with the important goal of spurring innovations that improve and save lives.”

Dr. Shuren announced that Dr. Michelle Tarver will take over as acting director of the CDRH on July 28th.  Dr. Tarver was hand-picked by Dr. Shuren to join the CDRH in 2009 and currently serves as the Deputy Center Director of Transformation.  Dr. Tarver’s work at the FDA has focused on patient engagement.  Dr. Tarver leads the Patient Engagement Advisory Committee and worked on the FDA’s Home as a Health Care Hub initiative. Dr. Tarver will continue to pursue the CDRH’s strategic priorities of (1) promoting a diverse workforce, (2) enhancing organizational agility, and (3) advancing health equity.

Tags

Dr. Jeff Shuren, FDA CDRH Director, to Retire Headshot

Zachary Messick

Zachary Messick’s practice focuses on patent prosecution and portfolio management, due diligence, and patent litigation. Zach currently assists clients in various fields of technology including medical devices, biotechnology, and software.

Zach received his J.D. from the University of Georgia School of Law where he was a member of the Journal of Intellectual Property Law. Before law school Zach attended Clemson University where he received a Bachelor of Science in Bioengineering.

View all posts published by Zachary Messick
By using this blog, you agree and understand that no information is being provided in the context of any attorney-client relationship. You further agree and understand that nothing herein is intended to be legal advice. This blog is solely informational in nature, and is not intended as, and should not be used as, a substitute for competent legal advice from a retained and licensed attorney in your state. Knobbe Martens LLP makes no representations or warranties as to the accuracy, completeness, timeliness or availability of the information in this blog. Knobbe Martens LLP will not be liable for any injury or damages relating to your use of, or access to, any such information. Knobbe Martens LLP undertakes no obligation to correct or update information on this blog, which may be incorrect or become incorrect or out of date over time. Knobbe Martens LLP reserves the right to alter or delete content or information on the blog at any time. This blog contains links and references to other websites and publications that you may find of interest. Knobbe Martens LLP does not control, promote, endorse or otherwise have any affiliation with any other websites or publications unless those websites or publications expressly state such an affiliation. Knobbe Martens LLP further has no responsibility for, and makes no representations regarding, the content, accuracy or any other aspect of the information in such websites or publications.
close modal